학술논문
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*
Document Type
Article
Author
Carvelli, J.; Piperoglou, C.; Vely, F.; Schleinitz, N.; Vivier, E.; Velly, L.; Guervilly, C.; Meziani, F.; Dellamonica, J.; Cordier, P.-Y.; Allardet-Servent, J.; Fraisse, M.; Barbar, S.D.; Lehingue, S.; Desgrouas, M.; Camou, F.; Demaria, O.; Karakunnel, J.; Fares, J.; Batista, L.; Rotolo, F.; Viotti, J.; Boyer-Chammard, A.; Lacombe, K.; Le Dault, E.; Carles, M.
Source
In: Critical Care Medicine . (Critical Care Medicine, 1 December 2022, 50(12):1788-1798)
Subject
Language
English
ISSN
15300293
00903493
00903493